Resistant bacterial infections

MGB Biopharma’s focus is on developing a completely new class of anti-infective medicine, starting with antibiotics which are based on Minor Groove Binder (MGBs) compounds.

The company’s experienced management team have dedicated their initial focus to the development of a new class of small molecule, with specific antibacterial activity based on a truly novel mechanism of action.

There are many drugs used to treat bacterial infections and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, many of these drugs are becoming less and less effective and a truly new class and novel MoA has not been seen since the year 2000. The combination of these factors has meant drug resistant strains of bacteria are now a serious health issue.

With their relatively unique approach, MGB Biopharma hope to provide a new class of drug in the field of antibacterial resistance. Specifically, they are developing a treatment for Clostridium difficile Infection (CDI). CDI is a serious and often life-threatening infection of the large intestine and is the most frequent cause of diarrhoea in hospitals and care homes. In the US alone, there are almost half a million cases every year associated with around 30,000 deaths; three people die of uncontrolled CDI each hour.

The company has completed a Phase IIa clinical trial with its lead drug candidate, MGB-BP-3. The study met its endpoints of safety, efficacy and dose selection and confirms that MGB-BP-3 has the potential to become the new gold standard, first-line treatment for CDI. Successful completion of the Phase IIa is a significant value inflection for the company and they are now looking for a development partner to progress the downstream clinical development of MGB-BP-3.

Sarah Hardy